Uncategorized
Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the third quarter of 2021, and provided updates on its ophthalmology pipeline. “The previous four months have been an exceptionally busy time at Ocular,” said Antony Mattessich, President and Chief Executive Officer. “We had a couple